{
    "xml": "<topic id=\"PHP8340\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/japanese-encephalitis-vaccine\" basename=\"japanese-encephalitis-vaccine\" title=\"JAPANESE ENCEPHALITIS VACCINE\">\n<title>JAPANESE ENCEPHALITIS VACCINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1323\" namespace=\"/interactions/list-of-drug-interactions/vaccines/japanese-encephalitis-vaccine\">Japanese Encephalitis Vaccine</xref>\n</p>\n<data name=\"vtmid\">13753911000001109</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_581448509\" title=\"Vaccines\">Vaccines</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" title=\"VACCINES\" namespace=\"/drug-classes/vaccines\">VACCINES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP57721\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/japanese-encephalitis-vaccine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against Japanese encephalitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2 months&#8211;2 years</p>\n<p>0.25&#8239;mL every 28&#8239;days for 2 doses, anterolateral thigh is preferred site of injection in infants, the subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 3&#8211;17 years</p>\n<p>0.5&#8239;mL every 28&#8239;days for 2 doses, deltoid muscle is preferred site in older children; anterolateral thigh is preferred in infants, the subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8239;mL every 28&#8239;days for 2 doses, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Booster dose</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8239;mL after 1&#8211;2&#8239;years, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders, for those at continued risk, the booster dose should be given 1 year after completing the primary course.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56631\" outputclass=\"sideEffects\" rev=\"1.21\" parent=\"/drugs/japanese-encephalitis-vaccine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cough</ph> (in children); <ph outputclass=\"sideEffect\">migraine</ph> (in adults); <ph outputclass=\"sideEffect\">vertigo</ph> (in adults)</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dyspnoea</ph> (in adults); <ph outputclass=\"sideEffect\">neuritis</ph> (in adults); <ph outputclass=\"sideEffect\">palpitation</ph> (in adults); <ph outputclass=\"sideEffect\">tachycardia</ph> (in adults); <ph outputclass=\"sideEffect\">thrombocytopenia</ph> (in adults)</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57301\" outputclass=\"pregnancy\" parent=\"/drugs/japanese-encephalitis-vaccine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Although manufacturer advises avoid because of limited information, miscarriage has been associated with Japanese encephalitis virus infection acquired during the first 2 trimesters of pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP8340-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/japanese-encephalitis-vaccine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74778\" title=\"Suspension for injection\" namespace=\"/drugs/japanese-encephalitis-vaccine/suspension-for-injection\">Suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78335\" namespace=\"/treatment-summaries/vaccines\" title=\"Vaccines\" count=\"1\" rel=\"backlink\">Vaccines</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1323\" namespace=\"/interactions/list-of-drug-interactions/vaccines/japanese-encephalitis-vaccine\" title=\"Japanese Encephalitis Vaccine\" count=\"1\" rel=\"link\">Japanese Encephalitis Vaccine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" namespace=\"/drug-classes/vaccines\" title=\"VACCINES\" count=\"1\" rel=\"link\">VACCINES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74778\" namespace=\"/drugs/japanese-encephalitis-vaccine/suspension-for-injection\" title=\"Suspension for injection\" count=\"1\" rel=\"link\">Suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP8340",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/japanese-encephalitis-vaccine",
    "basename": "japanese-encephalitis-vaccine",
    "title": "JAPANESE ENCEPHALITIS VACCINE",
    "interactants": [
        {
            "id": "bnf_int_1323",
            "label": "Japanese Encephalitis Vaccine"
        }
    ],
    "vtmid": "13753911000001109",
    "drugClassification": [
        "Vaccines"
    ],
    "inheritsFromClass": [
        "VACCINES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Immunisation against Japanese encephalitis",
                        "html": "Immunisation against Japanese encephalitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "0.25 mL every 28 days for 2 doses, anterolateral thigh is preferred site of injection in infants, the subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>0.25&#8239;mL every 28&#8239;days for 2 doses, anterolateral thigh is preferred site of injection in infants, the subcutaneous route may be used for patients with bleeding disorders.</p>",
                        "ageGroup": "2 months&#8211;2 years"
                    },
                    {
                        "textContent": "0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site in older children; anterolateral thigh is preferred in infants, the subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>0.5&#8239;mL every 28&#8239;days for 2 doses, deltoid muscle is preferred site in older children; anterolateral thigh is preferred in infants, the subcutaneous route may be used for patients with bleeding disorders.</p>",
                        "ageGroup": "3&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>0.5&#8239;mL every 28&#8239;days for 2 doses, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Booster dose",
                        "html": "Booster dose"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "0.5 mL after 1&#8211;2 years, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders, for those at continued risk, the booster dose should be given 1 year after completing the primary course.",
                        "html": "<p>0.5&#8239;mL after 1&#8211;2&#8239;years, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders, for those at continued risk, the booster dose should be given 1 year after completing the primary course.</p>"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Cough in children",
                        "html": "Cough in children",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon",
                            "patientType": "children"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "migraine in adults",
                        "html": "migraine in adults",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vertigo in adults",
                        "html": "vertigo in adults",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon",
                            "patientType": "adults"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Dyspnoea in adults",
                        "html": "Dyspnoea in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "neuritis in adults",
                        "html": "neuritis in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "palpitation in adults",
                        "html": "palpitation in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "tachycardia in adults",
                        "html": "tachycardia in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "thrombocytopenia in adults",
                        "html": "thrombocytopenia in adults",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare",
                            "patientType": "adults"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Although manufacturer advises avoid because of limited information, miscarriage has been associated with Japanese encephalitis virus infection acquired during the first 2 trimesters of pregnancy.",
                "html": "<p>Although manufacturer advises avoid because of limited information, miscarriage has been associated with Japanese encephalitis virus infection acquired during the first 2 trimesters of pregnancy.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74778",
                "label": "Suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78335",
                "label": "Vaccines",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1323",
                "label": "Japanese Encephalitis Vaccine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34568",
                "label": "VACCINES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74778",
                "label": "Suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}